Entities / Company
Eli Lilly and Company.
American pharmaceutical company
- Reports this week
- 16
- Active events
- 14
- Connections
- 905
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Trade data and legislative control are currently influencing market sentiment and corporate operations.Some support2 reports
-
Agreement between Eli Lilly and Hims & Hers Health expands access to Lilly's medicines.Some support2 reports
-
Trust plans to cut positions in Eli Lilly and Cardinal Health while seeking diversification from data-center exposure.Some support1 report
-
Nvidia is a top holding in VOO, which also holds Apple Inc. as a major position. Warren Buffett advises investing in S&P 500 ETFs, noting Eli Lilly as a key non-tech giant.Well supported10 reports
-
Lilly Canada sponsored an innovation challenge while HealthCareCAN highlighted access barriers in Canada.Some support1 report
-
Houthis actions and Iran's geopolitical moves are elevating gas prices, prompting investors to rotate into safer, low-growth sectors.Some support1 report
-
Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.Some support1 report
-
Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.Well supported18 reports1 development inside
-
Eli Lilly CEO David A. Ricks issued a company statement, coinciding with shares jumping in New York premarket trading.Some support3 reports
-
A fund prospectus was filed with the SEC, and Eli Lilly now constitutes about 17% of assets in the Health Care Select Sector SPDR Fund.Some support1 report
-
MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.Some support2 reports1 development inside
-
MarketBeat listed Eli Lilly and Company among stocks to watch on October 31, 2026.Some support4 reports
-
Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition.Some support2 reports1 development inside
-
Eli Lilly and Company now owns the drugmaker AtaiBeckley.Some support1 report
Earlier this month
-
Eli Lilly and Company developed the drug Retatrutide.Well supported6 reports
-
Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.Well supported3 reports1 development inside
-
CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.Some support1 report
-
Pharma company Eli Lilly sponsors a fashion event in Italy, featuring Miuccia Prada and Gigi Hadid, drawing criticism from advocates.Some support1 report
-
Nxera Pharma submitted an application for DMD treatment and exercised a licensing option, while Eli Lilly acquired Centessa.Some support1 report
-
Eli Lilly and Company promoted Khalil to president of Europe and Canada, and Laura Steele to president of the USA.Some support2 reports
-
Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.Well supported5 reports
-
Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.Some support2 reports
-
FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.Some support1 report
-
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Well supported33 reports6 developments inside
-
AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Speculative1 report1 development inside
-
Eli Lilly and Merck are combining therapies in clinical trials.Some support1 report
-
Eli Lilly and Company is expanding manufacturing operations with a $5 billion facility in Goochland County, Virginia.Some support1 report
-
Amazon is funding nuclear project development in Indiana, involving AtkinsRéalis, Braun, and Eli Lilly sites.Some support1 report
-
Major companies and central banks are meeting this week to discuss earnings reports and future rate outlooks.Some support1 report
-
Jamie Preston moved from Eli Lilly and Company to Elanco, where he was appointed EVP and CPO.Some support1 report
-
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.Well supported11 reports6 developments inside
-
BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.Some support1 report
-
Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Some support1 report1 development inside
-
Medicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.Some support1 report
-
Eli Lilly and Company announced a $4.5 billion investment in its facilities located in Indiana.Some support2 reports
-
Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly.Some support1 report1 development inside
-
Eli Lilly and Company acquired Point and established a supply agreement with EUZ.Some support1 report
-
Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.Some support5 reports
-
Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.Well supported11 reports3 developments inside
-
Eli Lilly's expansion in LEAP is driving local economic activity, benefiting from its proximity to Indianapolis.Some support1 report1 development inside
-
Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.Some support1 report
-
Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.Some support2 reports
-
Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.Some support1 report
-
Eli Lilly developed an investigational treatment in South Africa, with the National Prosecuting Authority supporting the handling of medicine cases.Some support1 report
-
Jim Cramer's trust bought Kimberly-Clark shares and exited Corning, while discussing the strong performance of companies like Eli Lilly on CNBC.Some support1 report
-
Eli Lilly and Company collaborated with Adlai Nortye Ltd. for a clinical trial supply agreement.Some support1 report
-
Eli Lilly's drug is being illegally sold in South Africa.Some support2 reports
-
FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Some support1 report
-
County judge handles school board vacancy, with Eli Lilly serving as superintendent.Some support1 report
-
Eli Lilly and Company and Lockheed Martin are mentioned as active market players.Some support1 report
-
Foghorn's FHD-909 trial advances with Eli Lilly and Company.Some support3 reports
-
Semiconductor stocks are declining, prompting portfolio adjustments, while Eli Lilly and Honeywell are also noted in market activity.Some support1 report
-
Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.Well supported5 reports2 developments inside
-
Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.Some support1 report
-
Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.Some support1 report
-
Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.Well supported3 reports
-
FDA granted Fast Track designation while PTC Therapeutics and Eli Lilly acquired assets from Sangamo Therapeutics.Some support1 report
-
Bank of America and Citigroup issued buy ratings and raised price targets on July 18, 2026.Some support2 reports
-
Eli Lilly and Company met with the Lebanon city council and announced plans for construction and local funding.Some support1 report
-
A fund has changed its holdings, replacing JPMorgan Chase with Eli Lilly and Company.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Eli Lilly and Company
Events traced to Eli Lilly and Company, step by step, newest first- Cloudbreak's potential pterygium drug may increase competition for Eli LillyCloudbreak's potential pterygium drug may increase competition for Eli LillyPossible
- Eli Lilly's market access may shift as CVS separates Caremark PBMEli Lilly's market access may shift as CVS separates Caremark PBMPossible
- New Sandoz CEO may shift competitive strategy against Eli LillySandoz's new CEO may shift competitive strategy against Eli LillyPossible
- How could CRISPR Therapeutics' new clinical data affect Eli Lilly and Company?CRISPR data may intensify competition for high-growth biotech market sharePossible
- AbbVie's pricing victory may increase competitive pressure on Eli LillyAbbVie's pricing victory may increase competitive pressure on Eli LillyPossible
- Novartis pipeline growth may intensify competition for Eli LillyNovartis's pipeline growth may intensify competition for Eli LillyPossible
See all 66 explainers
- Fiscal choices may tighten reimbursement for Eli Lilly and CompanyFiscal choices may tighten reimbursement for Eli Lilly and CompanyPossible
- Stricter FDA standards may raise compliance costs for Eli LillyStricter FDA standards could increase compliance costs for Eli Lilly and CompanyPossible
- How could the FDA lifting warnings on HRT products affect Eli Lilly and Company?New FDA data may boost market for hormone replacement therapyPossible
- City council changes may affect Eli Lilly's operational costsEli Lilly and Company may face increased operational costs due to city fee and infrastructure changes.Possible
- AbbVie's expanded migraine pipeline could challenge Eli LillyAbbVie's new migraine programs may increase competitive pressure on Eli Lilly.Possible
- New TGA sequence may change market access for Eli LillyNew regulatory sequence may alter pricing and market entry for Eli Lilly's productsPossible
- How could the end of Walmart's zero-dollar drug benefit affect Eli Lilly and Company?Former Walmart employees may drive up demand for high-cost GLP-1 drugsPossible
- Ceretas' ultrasound therapy may increase competition for Eli LillyCeretas' Alzheimer's therapy could increase competition for Eli LillyPossible
- FDA standards debate may change Eli Lilly's drug approval requirementsRegulatory debate over product standards could alter Eli Lilly's drug development pathPossible
- Merck's drug approvals intensify competition for Eli LillyIntensified competition from Merck's pipeline advancements could pressure Eli Lilly's market share.Likely
- Generic semaglutide entry may pressure Eli Lilly's market shareGeneric semaglutide entry may pressure Eli Lilly's market sharePossible
- J&J's healthcare stability could influence Eli Lilly's market standingJ&J's healthcare resilience may influence market sentiment for pharmaceutical peersPossible
- Medicare enrollment changes may affect Eli Lilly's prescription demandMedicare enrollment changes may affect Eli Lilly's prescription demandPossible
- New rare disease drug designation increases competition for Eli LillyNew rare disease drug designation increases competition for Eli LillyPossible
- How could the potential FDA approval of VDPHL01 affect Eli Lilly and Company?New hair loss treatment could increase competition for major pharma playersPossible
- Biotech rivalry may intensify competitive pressure on Eli LillyIncreased biotech rivalry may intensify competitive pressure on Eli Lilly's market sharePossible
- New Medicare care models may change how Eli Lilly is reimbursedNew Medicare care models may change how Eli Lilly is reimbursedPossible
- A regulatory discussion on mRNA immunotherapeutics may influence Eli Lilly and Company's market accessA regulatory discussion on mRNA immunotherapeutics may influence Eli Lilly and Company's market accessPossible
- Precision oncology funding may boost Eli Lilly's targeted treatment pipelinePrecision oncology funding may boost Eli Lilly's targeted treatment pipelinePossible
- New personalized cancer vaccine may intensify competition for Eli LillyNew personalized cancer vaccine platform could intensify competition for Eli LillyPossible
- AbbVie's new drug may challenge Eli Lilly in immunologyAbbVie's potential successor to Skyrizi could intensify competition with Eli Lilly.Possible
- How could AbbVie's acquisition of Apogee Therapeutics affect Eli Lilly and Company?AbbVie's acquisition may intensify competition in immunology marketPossible
- Medicare for All proposal may change drug pricing for Eli LillyEli Lilly and Company may face changes in pricing and reimbursement under Medicare for AllPossible
- Medicare scams may increase fraudulent billing risk for Eli LillyEli Lilly and Company may face increased risk of fraudulent billing and revenue loss due to Medicare scams.Possible
- New Medicare coverage may increase demand for Eli Lilly's drugsIncreased Medicare coverage in Arizona may boost demand for Eli Lilly's pharmaceuticalsPossible
- JNJ investor confidence may raise competitive bar for Eli LillyIncreased investor confidence in JNJ may raise competitive expectations for Eli Lilly and Company.Possible
- Local budget shifts may affect Eli Lilly's investment outlookLocal budget constraints may slow corporate investment for Eli Lilly and CompanyPossible
- FTC independence weakened, raising regulatory risk for Eli LillyThe politicization of the FTC could lead to inconsistent market enforcement against Eli Lilly and Company.Possible
- Eli Lilly may face pressure from new therapy approvals by rivalsEli Lilly may face increased competitive pressure from new approvals by rivalsPossible
- BioNTech partnerships could increase competitive pressure on Eli LillyBioNTech collaborations may increase competitive pressure on Eli LillyPossible
- Pliant's novel oncology data may increase competition for Eli LillyPliant's novel oncology data may increase competition for Eli LillyPossible
- Replimune's new melanoma drug may increase competition for Eli LillyReplimune's new melanoma drug may increase competition for Eli LillyPossible
- DKSH's new Middle East network may alter Eli Lilly's distribution scopeDKSH's new Middle East network may alter Eli Lilly's distribution scopePossible
- Hobart grant could boost skilled labor supply for Eli LillyHobart grant may improve skilled labor availability for Eli LillyPossible
- New Gilead HIV regimen may intensify competition for Eli LillyNew Gilead HIV regimen may intensify competition for Eli Lilly.Possible
- Moderna's vaccine combination increases competition for Eli LillyIncreased competitive pressure in advanced drug development for Eli LillyPossible
- J&J's strong drug performance may increase competitive pressure on Eli LillyJ&J's strong drug sales could intensify competition for Eli Lilly in key markets.Possible
- New Huntsville parkway may ease logistics for Eli LillyImproved Huntsville parkway may lower operational costs for Eli LillyPossible
- Eli Lilly may face market pressure from GLP-1 drug competitionIntense GLP-1 competition may pressure Eli Lilly and Company's market positionLikely
- Protein degrader boom intensifies rivalry for Eli LillyIntense market rivalry could challenge Eli Lilly and Company in high-growth therapeutic areasPossible
- MindWalk's talent boost increases competitive pressure on Eli LillyMindWalk's talent boost increases competitive pressure on Eli LillyPossible
- How could the NICE appraisal of a testosterone cream affect Eli Lilly and Company?NICE appraisal may determine market access for testosterone creamPossible
- Regulatory streamlining may increase competition for Eli LillyIncreased biosimilar competition may put pressure on Eli Lilly's market pricingPossible
- Gas tax suspensions may lower operational costs for Eli LillyLower fuel prices may reduce operational costs for Eli Lilly and CompanyPossible
- New AhR agonist development may increase competition for Eli LillyNew AhR agonist development may increase competition for Eli LillyPossible
- New Korean obesity drug may intensify price competition for Eli LillyNew Korean obesity drug may intensify price competition for Eli LillyPossible
- Improved local infrastructure may boost Eli Lilly and Company's operational reliabilityImproved local infrastructure may boost Eli Lilly and Company's operational reliability.Possible
- J&J's strategic pivot could change pharma competition for Eli LillyJ&J's focus shift may alter competitive landscape for Eli LillyPossible
- Economic stress may curb consumer demand for Eli Lilly's productsReduced consumer purchasing power may curb demand for Eli Lilly's productsPossible
- Increased regulatory enforcement against price gouging may raise compliance risks for Eli Lilly and CompanyIncreased regulatory enforcement against price gouging may raise compliance risks for Eli Lilly and Company.Possible
- New pill for Parkinson's could challenge Eli Lilly's neurological portfolioNew once-daily Parkinson's drug may increase competition for Eli LillyPossible
- Rising Medicare costs may shift drug spending burden to Eli Lilly's customersEli Lilly and Company may see shifts in drug revenue due to Medicare cost changesPossible
- J&J's strong pharma results may intensify competition for Eli LillyJ&J's strong pharma results may intensify competition for Eli LillyPossible
- Medicare price negotiation could challenge Eli Lilly's drug pricingEli Lilly and Company could face pressure on drug pricing and revenue streams.Possible
- JNJ and AbbVie co-commercialization intensifies competition for Eli LillyIncreased competition from JNJ and AbbVie may challenge Eli Lilly's market share.Possible
- Increased competition for investment capital may intensify market rivalry for Eli Lilly and CompanyIncreased competition for investment capital may intensify market rivalry for Eli Lilly and Company.Possible
- Medicare payment cut may change drug pricing for Eli LillyEli Lilly and Company may face changes in revenue due to proposed Medicare drug payment cutsPossible
- Bausch + Lomb's potential oral AMD drug may increase competition for Eli LillyBausch + Lomb's potential oral AMD drug may increase competition for Eli LillyPossible
- Eli Lilly's philanthropic investment reinforces Indiana youth programsEli Lilly and Company's philanthropic investment in Indiana continues through youth fundingLikely
- Medicare cuts may alter pricing and demand for Eli Lilly and CompanyMedicare cuts could potentially reduce revenue and alter pricing for Eli Lilly and CompanyPossible
Explainers that pass through Eli Lilly and Company
Eli Lilly and Company is a step on the way to someone elseAround Eli Lilly and Company this week
News at the entities that move Eli Lilly and Company most-
Medicare StructuralMedicare drug pricing program caused sales pressure on Publix.Moves Eli Lilly and Company
-
Johnson & Johnson OperationalJohnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Moves Eli Lilly and Company
-
FDA StructuralThe FDA approved Miplyffa for the treatment of Niemann-Pick disease.Moves Eli Lilly and Company
-
Novo Nordisk OperationalNovo Nordisk and Eric Lawitz presented research results at the AASLD meeting in Denver.Moves Eli Lilly and Company
-
Pfizer OperationalMedicus Pharma secured an ADC development deal with Pfizer and is advancing its SkinJect 005 study for FDA approval.Moves Eli Lilly and Company
-
Morgan Stanley OperationalSurrozen utilized conference platforms hosted by Morgan Stanley in South San Francisco on September 1, 2026.Moves Eli Lilly and Company
Connections
The 40 strongest of 905, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Johnson & Johnson Operational
The two pharmaceutical giants are engaged in intense, direct market competition across various therapeutic and growth segments.
-
David A. Ricks Structural
David A. Ricks serves as the Chair and CEO of Eli Lilly and Company.
-
FDA Structural
The FDA formally regulates Eli Lilly's drug development, approval, and market activities, determining product viability and market access.
-
David Ricks Structural
David Ricks serves as the Chief Executive Officer of Eli Lilly and Company.
-
Viking Therapeutics Operational
Viking Therapeutics and Eli Lilly are direct competitors in the GLP-1/GIP agonist market for obesity and weight management.
-
Novo Nordisk Operational
The two pharmaceutical companies are engaged in intense, high-stakes competition for global market leadership in the obesity and diabetes drug market.
-
Pfizer Operational
Pfizer and Eli Lilly are direct competitors vying for market share in high-growth pharmaceutical sectors, particularly GLP-1 weight loss and oncology.
-
Norges Bank Transactional
Norges Bank has repeatedly purchased new stakes and increased its holdings in Eli Lilly and Company.
Show all 40 connections
-
Verve Transactional
Eli Lilly and Company planned and initiated the acquisition of Verve Therapeutics for up to $1.3 billion.
-
Nicholas Noyes Structural
Nicholas Noyes served as a vice president and director of Eli Lilly and Company.
-
Generation Park Structural
Eli Lilly is establishing a $6.5 billion manufacturing facility at Generation Park.
-
Indiana Structural
Eli Lilly and Company is structurally integrated into Indiana through massive investments, operational expansion, and public health partnerships.
-
AbbVie Operational
AbbVie and Eli Lilly are direct competitors in the pharmaceutical market, vying for market share and therapeutic dominance.
-
Houston Structural
Eli Lilly and Company is establishing and operating a major $6.5 billion manufacturing facility in Houston.
-
Elanco Structural
Elanco was historically established as a division and subsidiary of Eli Lilly and Company.
-
Morgan Stanley Operational
Morgan Stanley actively influences Eli Lilly's market valuation through investment research, price targets, and rating adjustments.
-
Novo Nordisk Operational
The two companies are direct, high-stakes competitors in the global weight loss and diabetes drug markets, evidenced by market rivalry and active litigation.
-
Amgen Operational
Both companies are direct competitors in the advanced drug market, specializing in GLP-1 agonists and Lp(a) reduction therapies.
-
Medicare Structural
Medicare acts as the primary payer and regulatory gatekeeper, determining coverage and pricing for Eli Lilly's pharmaceutical products.
-
Khalil Structural
Khalil serves as President for Eli Lilly and Company in Europe and Canada.
-
ImClone Systems Structural
Eli Lilly acquired ImClone Systems, integrating its oncology franchise.
-
CVS Health Operational
CVS and Eli Lilly engage in a complex operational relationship involving both market competition (formulary decisions) and strategic partnerships for patient access and distribution.
-
AstraZeneca Operational
Eli Lilly and AstraZeneca are active competitors in the pharmaceutical market, vying for market share in oncology and obesity.
-
Securities and Exchange Commission Structural
Eli Lilly and Company is structurally required by the SEC to file institutional reports, such as Form 13F, regarding its share holdings.
-
Federal Trade Commission Structural
The Federal Trade Commission is formally regulating Eli Lilly, including mandating divestment and investigating market practices.
-
Merck Operational
Eli Lilly and Merck are direct, high-stakes competitors in the pharmaceutical market, particularly in GLP-1 and oncology therapeutics, frequently comparing sales and market positioning.
-
Health Resources and Services Administration Structural
Eli Lilly and Company is subject to compliance and oversight requirements and reporting mandates from the Health Resources and Services Administration.
-
Francisco Ramírez-Valle Structural
Francisco Ramírez-Valle serves as a Senior Vice President in the research division of Eli Lilly and Company.
-
Alabama Structural
Eli Lilly is committing $6 billion to establish a major operational presence with new manufacturing plants in Alabama.
-
VOO Structural
Eli Lilly is a major component holding within the VOO ETF.
-
Wang Li Structural
Wang Li serves as the head of the drug development center in China for Eli Lilly and Company.
-
Donald Trump Operational
Trump utilizes political pressure, tariffs, and policy agreements to influence Eli Lilly's manufacturing, pricing, and investment strategies.
-
China Structural
Eli Lilly's market access, drug sourcing, and revenue growth are structurally dependent on the Chinese regulatory environment and market conditions.
-
Merck KGaA Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Max Denning Structural
Max Denning serves as an associate vice president at Eli Lilly and Company.
-
Virginia Structural
Virginia provides regulatory and infrastructure support for Eli Lilly's ongoing manufacturing expansion.
-
Huntsville Structural
Eli Lilly is establishing a major manufacturing project and making a $6 billion investment in Huntsville.
-
Jim Cramer Operational
Jim Cramer actively provides market commentary, tracking, and bullish support for Eli Lilly and Company's stock and pipeline.
-
European Medicines Agency Structural
The EMA's regulatory recommendations and approvals directly determine Eli Lilly's market access and financial performance in Europe.
-
San Jacinto College Structural
Eli Lilly provides financial support and partners with San Jacinto College to build a skilled workforce and talent pipeline.
History
Events by the month they beganNovember 2026
6 events- Trade data and legislative control are currently influencing market sentiment and corporate operations.
- Agreement between Eli Lilly and Hims & Hers Health expands access to Lilly's medicines.
- Trust plans to cut positions in Eli Lilly and Cardinal Health while seeking diversification from data-center exposure.
- Lilly Canada sponsored an innovation challenge while HealthCareCAN highlighted access barriers in Canada.
- Houthis actions and Iran's geopolitical moves are elevating gas prices, prompting investors to rotate into safer, low-growth sectors.
- Orna Therapeutics was acquired by Eli Lilly and Company, a development within the RNA therapeutics sector.
October 2026
36 events- A fund prospectus was filed with the SEC, and Eli Lilly now constitutes about 17% of assets in the Health Care Select Sector SPDR Fund.
- MarketBeat listed Johnson & Johnson, AbbVie, Pfizer, Merck KGaA, Eli Lilly, Gilead Sciences, and Novartis as stocks to watch.
- MarketBeat listed Eli Lilly and Company among stocks to watch on October 31, 2026.
- Eli Lilly and Company now owns the drugmaker AtaiBeckley.
- CRISPR Therapeutics, Eli Lilly, and Johnson & Johnson are noted as major holdings in health care ETFs.
- Pharma company Eli Lilly sponsors a fashion event in Italy, featuring Miuccia Prada and Gigi Hadid, drawing criticism from advocates.
- Nxera Pharma submitted an application for DMD treatment and exercised a licensing option, while Eli Lilly acquired Centessa.
- Eli Lilly and Company promoted Khalil to president of Europe and Canada, and Laura Steele to president of the USA.
- FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.
- Eli Lilly and Merck are combining therapies in clinical trials.
- Eli Lilly and Company is expanding manufacturing operations with a $5 billion facility in Goochland County, Virginia.
- Amazon is funding nuclear project development in Indiana, involving AtkinsRéalis, Braun, and Eli Lilly sites.
- Major companies and central banks are meeting this week to discuss earnings reports and future rate outlooks.
- Jamie Preston moved from Eli Lilly and Company to Elanco, where he was appointed EVP and CPO.
- BMS, Eli Lilly, and Novo Nordisk are advancing GLP-1 portfolios, investing in manufacturing, and navigating regulatory approvals.
- Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.
- Medicare coverage is driving growth in the obesity drug market, leading to raised price targets for Eli Lilly.
- Eli Lilly and Company announced a $4.5 billion investment in its facilities located in Indiana.
- Eli Lilly and Company acquired Point and established a supply agreement with EUZ.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- Eli Lilly's expansion in LEAP is driving local economic activity, benefiting from its proximity to Indianapolis.
- Ken Griffin made investment moves on October 18, 2026, buying shares of AbbVie and Abbott Laboratories, and boosting Eli Lilly shares.
- Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.
- Eli Lilly developed an investigational treatment in South Africa, with the National Prosecuting Authority supporting the handling of medicine cases.
- Jim Cramer's trust bought Kimberly-Clark shares and exited Corning, while discussing the strong performance of companies like Eli Lilly on CNBC.
- Eli Lilly and Company collaborated with Adlai Nortye Ltd. for a clinical trial supply agreement.
- Eli Lilly's drug is being illegally sold in South Africa.
- FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.
- County judge handles school board vacancy, with Eli Lilly serving as superintendent.
- Eli Lilly and Company and Lockheed Martin are mentioned as active market players.
- Semiconductor stocks are declining, prompting portfolio adjustments, while Eli Lilly and Honeywell are also noted in market activity.
- Johnson & Johnson's MedTech segment missed Q3 estimates, while JNJ's P/E ratio was compared against Eli Lilly and Pfizer.
- Major pharmaceutical companies face safety questions and intense competition in the obesity drug market.
- FDA granted Fast Track designation while PTC Therapeutics and Eli Lilly acquired assets from Sangamo Therapeutics.
- Eli Lilly and Company met with the Lebanon city council and announced plans for construction and local funding.
- A fund has changed its holdings, replacing JPMorgan Chase with Eli Lilly and Company.
September 2026
3 events- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
- Kura Oncology created Caspian Therapeutics for diabetes research, which is backed by Eli Lilly, with a meeting scheduled in Milan.
Show 3 earlier months
August 2026
5 events- Eli Lilly CEO David A. Ricks issued a company statement, coinciding with shares jumping in New York premarket trading.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.
- Foghorn's FHD-909 trial advances with Eli Lilly and Company.
- Financial results and stock performance comparisons among AbbVie, Johnson & Johnson, Eli Lilly, and Merck.
July 2026
3 events- Nvidia is a top holding in VOO, which also holds Apple Inc. as a major position. Warren Buffett advises investing in S&P 500 ETFs, noting Eli Lilly as a key non-tech giant.
- Eli Lilly and Company is expanding into psychedelic and neuroscience pipelines, adding late-stage psychedelic assets through acquisition.
- Bank of America and Citigroup issued buy ratings and raised price targets on July 18, 2026.
June 2026
7 events- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Eli Lilly and Company developed the drug Retatrutide.
- Eli Lilly's tirzepatide proved more effective than Novo Nordisk's semaglutide in the obesity drug market.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly.